Program for the 2nd Norwegian Myeloma Workshop –
Clarion Hotel Brattøra, Trondheim 17.-18. October
Thursday 17th of October
12:00 - 13:00 Lunch
13:00 – 13:15 Opening
Tobias Slørdahl & Fredrik Schjesvold
13:15 – 13:30 The REMNANT study team - Fredrik Schjesvold
13:30 – 14:30 The clinical outline and protocol questions to solve - Fredrik Schjesvold / Anne-Marie Rasmussen
14:30 – 14:45 Break
14:45 – 15:15 Budget overview and additional applications - Anne-Marie Rasmussen
15:15 – 16:15 Flow cytometry and biobanking - Mona Fenstad og Liv Osnes
16:15 – 16:30 Break
15:30 – 16:00 Additional research questions including QOL - pending funding - Anne-Marie Rasmussen
16:00 – 16:45 Formalities of the national collaboration - Contracts and so on - Anne-Marie Rasmussen
16:45 - 17:15 Discussion
17:15 - 17:30 Recap and conclusion - Fredrik Schjesvold
18:00 Dinner
Friday 18th of October
08:00 – 08:30 TAK-inhibitors in myeloma
Kristian Starheim, NTNU
08:30 – 09:00 The journey from patient – preparation – storage and utilization – The organization of the Norwegian Myeloma Biobank – Biobank 1
Lill Anny Gunnes Grøseth, Biobank 1
09:00 – 10:30 Increasing the activity of bone morphogenetic proteins as a treatment strategy in multiple myeloma
Toril Holien PhD, NTNU
09:30 - 09:45 Break
09:45 –10:00 The Myeloma-HCQ study - Update
Tobias S. Slørdahl, NTNU/St. Olavs hospital
10:00 – 11:00 How can the pharmaceutical companies contribute in investigator initiated Norwegian Trials?
Knut Steffensen, Hilde Abrahamsen and Hege Riisa. Discussion
11:00 – 11:15 Break
11:15 – 11:45 Immunotherapy targeting a tumor-associated ganglioside [No industry]
Anders Tveita, Oslo University Hospital
11:45 – 12:00 Update on MRD in myeloma
Mona Fenstad, St. Olavs hospital
12:00 - 12:30 Små sykehus og kliniske studier – Hvordan best delta?
Diskusjon med innledning av Jon Hjalmar Sørbø, Levanger sykehus
12:30 – 13:00 Discussions on cooperation and conclusions
13:00 Lunch and goodbye